21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics
Key Takeaways
- The four pharmacoeconomic analyses are distinguished by how outcomes are measured: cost-minimization assumes proven equivalent outcomes and compares cost only, cost-effectiveness reports cost per natural unit such as cost per exacerbation avoided, cost-utility reports cost per quality-adjusted life year, and cost-benefit converts outcomes to currency.
- The incremental cost-effectiveness ratio is the difference in cost between two strategies divided by the difference in effect; a lower ICER is more favorable, and US willingness-to-pay thresholds are commonly cited between $50,000 and $150,000 per quality-adjusted life year.
- Pediatric economic evaluations must use a societal or at least caregiver-inclusive perspective, because caregiver lost productivity and travel often exceed direct medical costs, and must use pediatric-validated utility instruments such as EQ-5D-Y, HUI2, or HUI3 rather than adult instruments.
- Because children accrue decades of quality-adjusted life years from a successful intervention while adult discounting at the conventional 3% annual rate heavily devalues distant benefits, the choice of discount rate can change whether a pediatric therapy appears cost-effective.
- Children's hospitals became eligible 340B covered entities under the Deficit Reduction Act of 2005 and are expressly carved out of the 340B orphan drug exclusion that applies to free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals; 340B pricing, standardized concentrations, dose rounding, and single-dose container sharing are the main levers for containing pediatric drug cost without changing therapy.
21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics
The BPS Pediatric Pharmacy content outline lists Pharmacoeconomics (e.g., cost-containment, formulary management) under Practice Management. On the examination this appears in two guises: a methodological question that asks you to name the right analysis type or compute an incremental cost-effectiveness ratio, and an applied question that asks how a pediatric pharmacist should present a therapeutic to a Pharmacy and Therapeutics committee.
The Four Analyses, Distinguished by How Outcomes Are Measured
Every pharmacoeconomic analysis measures costs in currency. What separates the four types is the unit in which outcomes are expressed.
| Analysis | Outcome unit | When it is the right choice | Pediatric example |
|---|---|---|---|
| Cost-minimization (CMA) | None — outcomes assumed proven equivalent | Only valid after equivalence has been demonstrated, not assumed | Two interchangeable third-generation cephalosporins with identical spectrum and identical clinical cure rates; choose on acquisition plus preparation cost |
| Cost-effectiveness (CEA) | A natural clinical unit | Comparators share the same outcome measure | Cost per vaso-occlusive crisis avoided; cost per pulmonary exacerbation averted; cost per case of respiratory syncytial virus hospitalization prevented |
| Cost-utility (CUA) | Quality-adjusted life years (QALYs) | Comparing across different diseases or when quality of life dominates | Cost per QALY of a CFTR modulator versus best supportive care; the standard for formulary and payer decisions |
| Cost-benefit (CBA) | Currency — outcomes monetized | Comparing programs with entirely unlike outcomes; yields a net monetary benefit or benefit-to-cost ratio | A hospital-wide pediatric antimicrobial stewardship program versus a medication reconciliation program |
[!IMPORTANT] The single most common examination error is calling an analysis a cost-minimization study when equivalence was assumed rather than demonstrated. If the trial did not establish equivalence, the correct design is a cost-effectiveness analysis.
The Incremental Cost-Effectiveness Ratio
The ICER is the extra cost purchased per extra unit of benefit. Lower is more favorable.
Worked example. A new inhaled therapy for pediatric asthma costs $4,800 per patient-year and produces 0.62 exacerbations per year. Standard therapy costs $1,200 per patient-year and produces 0.94 exacerbations per year.
Interpretation requires a benchmark: if the average pediatric asthma admission costs $14,000, the new therapy is plausibly cost-saving from the payer perspective; if most avoided exacerbations would have been managed in clinic, it is not.
Dominance. A strategy that is both less costly and more effective is dominant and no ratio is needed. A strategy that is more costly and less effective is dominated and should be rejected outright. ICERs are only informative in the trade-off quadrants.
Willingness-to-pay. In cost-utility analysis, results are judged against a threshold. United States analyses commonly cite $50,000 to $150,000 per QALY; the Institute for Clinical and Economic Review typically reports a $100,000 to $150,000 per QALY range. No threshold is legally binding in the United States, and none accounts well for ultra-rare pediatric disease.
What Makes Pediatric Pharmacoeconomics Different
FOUR PEDIATRIC-SPECIFIC METHODOLOGIC PROBLEMS
1. PERSPECTIVE A payer perspective misses the parent who left work
for 9 days. In pediatrics, caregiver productivity loss
and travel frequently exceed direct medical cost, so a
SOCIETAL perspective is usually required for a fair
comparison.
2. UTILITY Adult EQ-5D is not validated in children. Use EQ-5D-Y,
MEASUREMENT HUI2/HUI3, or PedsQL. Young children cannot self-report,
so PROXY (caregiver) report is used and systematically
differs from child self-report.
3. TIME HORIZON A cure at age 3 yields ~75 years of benefit. Trials run
& DISCOUNTING 2 years. Modeling is unavoidable, and at the conventional
3% annual discount rate a QALY 60 years away is worth
about 17% of one today - which structurally disadvantages
pediatric interventions.
4. EVIDENCE Small populations, few randomized pediatric trials, and
SCARCITY heavy reliance on extrapolation from adults widen every
confidence interval in the model.
Because of item 3, well-conducted pediatric analyses report results at multiple discount rates (commonly 0%, 1.5%, and 3%) in sensitivity analysis. A therapy that is cost-effective at 0% and not at 3% should be described that way, not asserted to be either.
Sensitivity analysis is what separates a credible model from an advertisement. One-way sensitivity analysis varies a single input across its plausible range; probabilistic sensitivity analysis samples all inputs simultaneously from their distributions and reports the probability of cost-effectiveness at a given threshold.
Formulary Management and the P&T Committee
The Pharmacy and Therapeutics (P&T) committee is the governing body for formulary decisions, and the evidence-appraisal and excipient-safety steps of a pediatric formulary review are detailed in the off-label pharmacotherapy section of the evidence chapter. The economic contribution a pharmacist makes to that review is a single discipline: present total cost of care, not acquisition cost. Acquisition price is one line in a budget that also contains nursing preparation and administration time, wasted drug, monitoring laboratory draws, treatment of adverse effects, and length of stay. A product with a higher unit price that is available as a ready-to-administer syringe in a standard concentration frequently wins on total cost while also reducing error risk.
| Formulary tool | Definition | Pediatric caution |
|---|---|---|
| Closed formulary | Only listed agents stocked; non-formulary requires an exception | Must preserve rapid access for orphan and rescue therapies |
| Therapeutic interchange | Pre-authorized substitution of a therapeutically equivalent agent under a P&T-approved protocol | Requires a documented pediatric dose conversion, not an adult one |
| Restriction criteria | Use limited by service, indication, or duration | Most common for antimicrobials, IVIG, and biologics |
| Prior authorization | Payer-side approval requirement | A major access barrier for off-label pediatric use, which is the norm rather than the exception in children |
| Medication use evaluation (MUE) | Structured retrospective or concurrent review against criteria | Closes the loop after a formulary addition |
Cost-Containment Levers Specific to Pediatrics
- 340B Drug Pricing Program. Freestanding children's hospitals became eligible covered entities under the Deficit Reduction Act of 2005, joining disproportionate-share hospitals and federal grantees. The program requires discounted outpatient drug pricing from participating manufacturers. Compliance obligations are strict: no duplicate discounts with Medicaid rebates, no diversion to ineligible patients, and auditable records. A frequently misremembered detail: the 340B orphan drug exclusion does not apply to children's hospitals. That exclusion reaches free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals, and children's hospitals are expressly carved out of it — so a children's hospital can access 340B pricing on orphan-designated drugs, which matters enormously in a population where much of the high-cost formulary is orphan-designated.
- Drug waste is a pediatric-specific cost driver. A 40 mg dose drawn from a 500 mg single-dose vial wastes 92% of the product. Countermeasures include standardized concentrations (the ASHP Standardize 4 Safety initiative), dose rounding within a defined tolerance, batch preparation of common doses, and vial sharing under USP <797>, where a single-dose container entered only in ISO Class 5 or cleaner air may be used for up to 12 hours after initial entry provided labeled storage conditions are maintained — a container punctured in worse than ISO Class 5 air must be discarded immediately.
- Dose rounding is a safety intervention as well as an economy: rounding to a syringe-measurable volume eliminates the un-measurable 0.13 mL order that invites a tenfold error.
- Antimicrobial stewardship remains the highest-yield cost-containment program in a children's hospital, with intravenous-to-oral conversion, automatic duration stops, and de-escalation on culture results delivering savings that dwarf acquisition-price negotiation.
- Biosimilar adoption in pediatric rheumatology, gastroenterology, and oncology supportive care produces large savings, but requires attention to device usability for a child or caregiver and to state substitution law.
Practice Pearls & BCPPS Exam Traps
- Exam Trap 1: Cost-utility analysis is the subtype of cost-effectiveness analysis whose outcome unit is the QALY. If the question names QALYs, the answer is cost-utility even when the stem says "cost-effectiveness."
- Exam Trap 2: A lower ICER is better. Options that describe a higher ICER as more favorable are inverted.
- Exam Trap 3: A dominant strategy — cheaper and more effective — does not need an ICER at all. Computing one is a distractor.
- Board Rule: When presenting any pediatric therapeutic to P&T, the availability of an age-appropriate dosage form and the excipient load carried by the alternative are decision-relevant, not footnotes. A cheaper product that must be extemporaneously compounded with a propylene glycol vehicle for a neonate is not actually cheaper.
A children's hospital P&T committee reviews a new subcutaneous biologic for severe pediatric atopic dermatitis. Investigators modeled lifetime costs and outcomes, measured health states with the EQ-5D-Y instrument, and reported a result of $96,400 per quality-adjusted life year gained versus standard topical therapy. Which type of pharmacoeconomic analysis was performed, and how should the result be interpreted?
A pediatric pharmacist compares two prophylaxis strategies for a pediatric population. Strategy A costs $2,000 per patient and yields 8.40 quality-adjusted life years. Strategy B costs $5,600 per patient and yields 8.85 quality-adjusted life years. What is the incremental cost-effectiveness ratio of Strategy B versus Strategy A?
A freestanding children's hospital pharmacy director is building a cost-containment plan. Which intervention most directly addresses the drug-waste problem that is specific to pediatric dosing?